サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1179906

胸腔カテーテルの世界市場-2023-2030

Global Pleural Catheters Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 180 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
胸腔カテーテルの世界市場-2023-2030
出版日: 2023年01月05日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

胸腔カテーテルの世界市場規模は、予測期間（2023～2030年）にCAGR6.2％で成長するとされています。

胸腔カテーテルは、胸部を切開（カット）して胸腔内に挿入する柔軟なチューブです。カテーテルは胸腔内に留置され、余分な液体を回収するための多くの穴が開いています。胸腔カテーテルは、患者のQOL（生活の質）、患者の安全、臨床医の効率を向上させ、入院を回避し、最小限の介入で効果的に症状を緩和するための第一選択治療として使用されています。

市場力学

胸腔カテーテルは、胸膜癒着術が失敗した場合や禁忌とされた場合の悪性胸水に対する治療オプションとして、世界中でより一般的になってきています。胸腔カテーテルは、患者の生活の質、安全性、臨床医の効率性を改善するための第一選択治療として使用されています。胸腔カテーテル市場の成長を促す重要な要因として、病院への入院をなくし、最小限の介入で効果的な症状の緩和を実現することが挙げられます。

世界的に心血管系疾患の有病率が高まっていることが、市場の成長を後押しすると予想されます。

米国疾病対策予防センターによると、2020年、心臓病により男性382,776人（男性の死亡者数の4人に1人）、女性314,186人（女性の死亡者数の5人に1人）が死亡しています。CVDは、冠動脈疾患、脳血管疾患、リウマチ性心疾患など、心臓や血管の疾患群を指します。CVDによる死亡の5分の4以上は心臓発作と脳卒中によるものであり、その3分の1は70歳未満の早死にです。

胸水の最も一般的な原因は、うっ血性心不全（CHF）です。胸膜微小循環の静水圧の増大が、リンパ管の過剰な液体を再吸収する能力を上回ると、胸水が胸腔に貯留します。胸水はCHF患者の約70％に発生するが、基礎疾患の治療により、通常、胸水は再吸収されます。症状のある患者では、薬理学的治療効果を待つ間、治療的胸腔穿刺がしばしば考慮されます。患者は、最適な医学的管理にもかかわらず、症候性胸水が再発することがあります。したがって、留置胸腔カテーテルはうっ血性心不全に有効で忍容性が高く、合併症率も低く、特に非移植患者にとっては妥当な治療法であると考えられます。以上のことから、予測期間中に市場を牽引することが期待されます。

胸腔カテーテルに関連する合併症が市場成長の妨げになると予想されます。

胸腔カテーテルは、心臓関連の慢性疾患の再発を患う患者によく使用されます。鎮静剤を使用せずに簡単に挿入できますが、その使用には多くの合併症が伴います。カテーテルに関連する胸膜感染症は、患者さんに最も多く見られます。その他、胸腔カテーテルの使用に伴うリスクとして、カテーテル管転移、重度の胸痛、チューブ脱落などがあります。胸腔カテーテルが体内に長期間存在することに関連するこうした合併症は、患者に問題を引き起こし、市場成長の妨げとなる可能性があります。

COVID-19の影響分析

COVID-19の大流行により、胸膜疾患管理に関する新たな課題が生まれました。胸膜疾患に対する日常的な医療行為とサービス提供は、リソースと人材が急性疾患のCOVID-19患者の管理に振り向けられたため、深刻な混乱に陥っています。このため、胸膜および肺がんサービスの提供にも大きな混乱が生じ、この大流行の刻々と変化する状況を反映するために、ガイドラインが定期的に更新されています。例えば、英国胸部学会（BTS）のCOVID-19勧告では、患者とスタッフの安全を確保しつつ、病院への訪問と入院を減らすために、がんが疑われる場合の診断経路を継続することが提唱されています。さらに、症候性悪性胸水のある患者には、治療的大容量吸引か第一選択の留置胸腔カテーテル（IPC）を受けることを勧め、胸腔ドレーンやタルク胸膜癒着のための入院の必要性を回避しています。家族は可能な限りIPCを排出する訓練を受け、何度も地区看護師を訪問することによるリスクを軽減する必要があります。地域の専門知識にもよるが、抗がん剤治療の候補であるがん患者は、IPCを伴う/伴わない日帰り医療胸腔鏡検査や画像誘導胸膜生検を受けるべきです。このように、上記の要因から、市場は影響を受け、予測期間中に改善されることが期待されます。

目次

第1章 調査手法と調査範囲

  • 調査手法
  • 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場影響要因
    • 促進要因
      • 世界の心血管疾患の増加により、市場の成長が見込まれます。
    • 抑制要因
      • 胸腔カテーテルに関連する合併症が市場成長を阻害すると予想されます。
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターの5つの力
  • サプライチェーン
  • プライシング分析

第6章 COVID-19の分析

  • COVID-19の市場分析
    • COVID-19以前の市場シナリオ
    • COVID-19の現在の市場シナリオ
    • COVID-19の後、または将来のシナリオ
  • COVID-19の中での価格ダイナミクス
  • 需要-供給スペクトラム
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • まとめ

第7章 適応症別

  • 悪性胸水
  • 非悪性再発性胸水
  • 幽門胸膜炎
  • 脳浮腫
  • 血胸

第8章 エンドユーザー別

  • 病院
  • 外来手術センター
  • その他

第9章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他の南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第10章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A（合併・買収）分析

第11章 企業プロファイル

  • Medtronic
    • 企業概要
    • 製品ポートフォリオと説明
    • 主なハイライト
    • 財務概要
  • Teleflex Incorporated
  • Ply Gem Holdings Inc
  • Smiths Group plc
  • Medela AG
  • ATMOS MedizinTechnik GmbH & Co. KG
  • ARGON MEDICAL
  • BD
  • MAQUET Holding B.V. & Co. KG
  • LivaNova PLC
  • Cook Medical

第12章 胸腔カテーテルの世界市場-DataM

目次
Product Code: DMMD1451

Market Overview

The global pleural catheters market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 6.2% during the forecast period (2023-2030).

The pleural catheter is a flexible tube inserted through an incision (cut) in the chest and placed in the pleural cavity. The catheter sits in the pleural cavity and has many holes to collect the extra fluid. Pleural catheters are used as a first-line therapy to improve patient quality of life, patient safety, and clinician efficiency-freedom from hospitalization and effective symptomatic relief with minimal interventions.

Market Dynamics

Pleural catheters are becoming more popular worldwide as a treatment option for malignant pleural effusions when pleurodesis has failed or is contraindicated. Pleural catheters are used as first-line therapy to improve patient quality of life, safety, and clinician efficiency. Some critical factors driving the growth of the pleural catheter market include eliminating hospital admissions and providing effective symptomatic relief with minimal interventions.

The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.

According to the Centers for Disease Control and Prevention, 2020, heart disease killed 382,776 men (1 in 4 male deaths) and 314,186 women (1 in 5 female deaths). CVDs are a group of heart and blood vessel disorders, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70.

The most common cause of the pleural effusion is congestive heart failure (CHF). When increased hydrostatic pressure in the pleural microcirculation exceeds the capacity of lymphatic vessels to reabsorb the excess fluid, fluid accumulates in the pleural space. Although pleural effusion occurs in approximately 70% of CHF patients, treatment of the underlying disease usually results in fluid reabsorption. In symptomatic patients, therapeutic thoracentesis is frequently considered while waiting for a pharmacological treatment effect. Patients may experience recurrent symptomatic pleural effusions despite optimal medical management. Therefore, indwelling pleural catheters are effective and well tolerated in congestive heart failure, have a low complication rate, and may be considered a reasonable treatment option, particularly for nontransplant candidates. Thus, from the above factors, the market is expected to drive in the forecast period..

Complications Associated with pleural catheters are expected to hamper the market growth.

Pleural catheters are commonly used in patients suffering from recurrent heart-related chronic diseases. Although they are simple to insert without sedation, many complications are associated with their use. Catheter-related pleural infections are the most common in patients. Other risks associated with using pleural catheters in patients include catheter tract metastases, severe chest pain, tube dislocation, etc. Such complications related to the long-term presence of pleural catheters in the body can cause problems for patients, hampering market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has created new challenges for pleural disease management. Routine medical practice and service provision for pleural diseases have been severely disrupted as resources and personnel have been redirected to manage acutely ill COVID-19 patients. This has also resulted in significant disruptions in the delivery of pleural and lung cancer services, with guidelines being updated regularly to reflect the ever-changing landscape of this pandemic. For instance, the British Thoracic Society (BTS) COVID-19 recommendations advocate for the continuation of diagnostic pathways for suspected cancer to reduce hospital visits and admissions while ensuring patient and staff safety. Moreover, patients with symptomatic malignant pleural effusions are advised to undergo either large-volume therapeutic aspirations or first-line indwelling pleural catheters (IPC), avoiding the need for hospitalization for chest drain and talc pleurodesis. Family members should be trained to drain IPCs whenever possible, reducing the risks posed by multiple district nurse visits. Depending on local expertise, patients with cancer who are candidates for anti-cancer therapy should have a day-case medical thoracoscopy with/without an IPC or image-guided pleural biopsies. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Malignant Pleural Effusions segment is expected to hold the largest market share in pleural catheters

The malignant pleural effusions segment accounted for the largest market share in 2021. Many diseases can cause pleural effusion. It has been observed in infections, other diseases, and cancers. In general, fluid accumulates in the pleural space when there is an excess of fluid, a decrease in fluid absorption, or both. If the effusion is caused by cancer cells in the fluid, it is referred to as a "malignant pleural effusion" or MPE. When cells from lung cancer or another type of cancer spread to the pleural space, an MPE forms. These cancer cells increase pleural fluid production while decreasing fluid absorption.

Furthermore, people with lung cancer, breast cancer, and lymphoma (lymphatic tissue cancer) are more likely to get an MPE. Another common cause of MPE is mesothelioma (a rare cancer of the pleura). MPE can also be caused by cancer that has spread from the stomach, kidney, ovaries, or colon. Therefore, the increasing prevalence of cancer worldwide is expected to drive market growth in the forecast period. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed in 2020 is estimated to be 19.3 million, with nearly 10.0 million deaths due to cancer. GLOBOCAN predicts that cancer cases will reach 28.4 million by 2040. Female breast cancer has surpassed lung cancer as the most common cancer in the world (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%).

Additionally, in terms of cancer-related mortality, lung cancer is the leading cause, accounting for 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%). Men are more likely to develop lung, prostate, and colorectal cancers, whereas women are more likely to develop breast, colorectal, and lung cancers. The top ten cancers account for more than 60% of cancer incidence and 70% of cancer mortality. As a result, the demand for indwelling pleural catheters (IPC) has increased because this device is a small catheter placed under your skin and into the pleural fluid, allowing for repeated drainage at home (without any more needle sticks) to relieve symptoms. These catheters are placed as an outpatient procedure under local anesthesia. The catheter is safe and simple to use and may eventually allow the lung to expand fully up to the chest wall. After the fluid buildup subsides, many patients can have the catheter removed after 2-3 months. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global pleural catheters market

North America region accounted for the largest market share in 2021. The increasing prevalence of pleural diseases, rising cases of cardiovascular disease, cancer and infectious disease, increasing number of thoracic surgeries, increasing demand for minimally invasive processes and favorable reimbursement policies are the factors to drive the market in the forecast period. For instance, according to the National Center For Biotechnology Information Report 2022, pleural effusion is the most common pleural disease, affecting 1.5 million patients in the United States annually. Pleural effusions can be caused by a variety of conditions, including lung diseases such as pneumonia and asbestos exposure, systemic diseases such as lupus and rheumatoid arthritis, or the pleural manifestation of diseases that affect other organs such as congestive heart failure, pancreatitis, or conditions local to the pleura such as pleural infections and mesothelioma. Therefore, it has increased the demand for pleural catheters. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the pleural catheters market are Medtronic, Teleflex Incorporated, Ply Gem Holdings Inc, Smiths Group plc, Medela AG, ATMOS MedizinTechnik GmbH & Co. KG, ARGON MEDICAL, BD, MAQUET Holding B.V. & Co. KG, LivaNova PLC and Cook Medical.

Teleflex Incorporated:

Overview:

Teleflex Incorporated is an American provider of specialty medical devices for various critical care and surgical procedures. The firm reports seven segments: vascular access, interventional, surgical, anesthesia, interventional urology, original-equipment manufacturing, and all others. Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rusch, UroLift and Weck - trusted brands united by a common sense of purpose. The company's geographic exposure is predominantly in the United States, accounting for 60% of revenue, with overseas markets accounting for the remaining 40%.

Product Portfolio:

Arrow-Clarke Thoracentesis Device: The Arrow-Clarke Thoracentesis Device permits the removal of fluids from the pleural space and provides access to infuse chemotherapeutic or sclerosing agents.

The global pleural catheters market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Complications Associated with pleural catheters are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Supply Chain
  • 5.3. Pricing Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Indication

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication Type
    • 7.1.2. Market Attractiveness Index, By Indication
  • 7.2. Malignant Pleural Effusions*
      • 7.2.1.1. Introduction
      • 7.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Non-Malignant Recurrent Effusions
  • 7.4. Chylothorax
  • 7.5. Empyema
  • 7.6. Haemothorax

8. By End user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 8.1.2. Market Attractiveness Index, By End user
  • 8.2. Hospitals*
      • 8.2.1.1. Introduction
      • 8.2.1.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Ambulatory Surgical Center
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.5.1. Germany
      • 9.3.5.2. U.K.
      • 9.3.5.3. France
      • 9.3.5.4. Italy
      • 9.3.5.5. Spain
      • 9.3.5.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. Brazil
      • 9.4.5.2. Argentina
      • 9.4.5.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. China
      • 9.5.5.2. India
      • 9.5.5.3. Japan
      • 9.5.5.4. Australia
      • 9.5.5.5. Rest of Asia Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Medtronic*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Teleflex Incorporated
  • 11.3. Ply Gem Holdings Inc
  • 11.4. Smiths Group plc
  • 11.5. Medela AG
  • 11.6. ATMOS MedizinTechnik GmbH & Co. KG
  • 11.7. ARGON MEDICAL
  • 11.8. BD
  • 11.9. MAQUET Holding B.V. & Co. KG
  • 11.10. LivaNova PLC
  • 11.11. Cook Medical

LIST NOT EXHAUSTIVE

12. Global Pleural Catheters Market- DataM

  • 12.1. Appendix
  • 12.2. About Us and Applications
  • 12.3. Contact Us